JP2022530095A5 - - Google Patents

Info

Publication number
JP2022530095A5
JP2022530095A5 JP2021563234A JP2021563234A JP2022530095A5 JP 2022530095 A5 JP2022530095 A5 JP 2022530095A5 JP 2021563234 A JP2021563234 A JP 2021563234A JP 2021563234 A JP2021563234 A JP 2021563234A JP 2022530095 A5 JP2022530095 A5 JP 2022530095A5
Authority
JP
Japan
Prior art keywords
sequence
raav
seq
mirna target
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530095A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029642 external-priority patent/WO2020219766A1/en
Publication of JP2022530095A publication Critical patent/JP2022530095A/ja
Publication of JP2022530095A5 publication Critical patent/JP2022530095A5/ja
Pending legal-status Critical Current

Links

JP2021563234A 2019-04-24 2020-04-23 レット症候群の治療に有用な組成物 Pending JP2022530095A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837947P 2019-04-24 2019-04-24
US62/837,947 2019-04-24
PCT/US2020/029642 WO2020219766A1 (en) 2019-04-24 2020-04-23 Compositions useful in treatment of rett syndrome

Publications (2)

Publication Number Publication Date
JP2022530095A JP2022530095A (ja) 2022-06-27
JP2022530095A5 true JP2022530095A5 (cg-RX-API-DMAC7.html) 2023-04-28

Family

ID=72941315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563234A Pending JP2022530095A (ja) 2019-04-24 2020-04-23 レット症候群の治療に有用な組成物

Country Status (9)

Country Link
US (1) US20220202960A1 (cg-RX-API-DMAC7.html)
EP (1) EP3973060A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022530095A (cg-RX-API-DMAC7.html)
KR (1) KR20220003553A (cg-RX-API-DMAC7.html)
CN (1) CN114026236A (cg-RX-API-DMAC7.html)
AU (1) AU2020261051A1 (cg-RX-API-DMAC7.html)
CA (1) CA3133889A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111279QA (cg-RX-API-DMAC7.html)
WO (1) WO2020219766A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298138A (en) * 2020-05-12 2023-01-01 Univ Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2022094078A1 (en) * 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
KR20240100490A (ko) * 2021-10-18 2024-07-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Cdkl5 결핍 장애(cdd)의 치료에 유용한 조성물
WO2023205657A2 (en) * 2022-04-18 2023-10-26 City Of Hope Compositions for restoring mecp2 gene function and methods of use thereof
US20260139232A1 (en) * 2022-10-10 2026-05-21 Passage Bio, Inc. Method of purifying full recombinant aav particles
CN121175427A (zh) * 2023-05-15 2025-12-19 上海金珂博生物技术有限公司 一种Rett综合症的基因治疗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099196A1 (en) * 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
DK2002003T3 (en) * 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
DK2010563T3 (da) * 2006-04-07 2011-05-23 Univ Goettingen Georg August Syntetisk MeCP2 sekvens til proteinsubstitutionsterapi
US9415121B2 (en) * 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
TW201837170A (zh) * 2017-02-28 2018-10-16 賓州大學委員會 新穎aav媒介的流感疫苗
RS65241B1 (sr) * 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
RU2019133002A (ru) * 2017-03-24 2021-04-26 Зе Юнивёрсити Корт Оф Зе Юнивёрсити Оф Эдинбург ЭКСПРЕССИОННЫЕ КАССЕТЫ MeCP2
EP3635122A4 (en) * 2017-06-06 2021-03-31 University of Massachusetts SELF-REGULATING AAV VECTORS FOR THE SAFE EXPRESSION OF MECP2 IN RETT SYNDROME

Similar Documents

Publication Publication Date Title
JP2022517174A5 (cg-RX-API-DMAC7.html)
JP2023526310A5 (cg-RX-API-DMAC7.html)
JP2022530633A5 (cg-RX-API-DMAC7.html)
JP2022549380A5 (cg-RX-API-DMAC7.html)
JP2026027271A5 (cg-RX-API-DMAC7.html)
JP2022530544A5 (cg-RX-API-DMAC7.html)
JP2024095717A5 (cg-RX-API-DMAC7.html)
JP2022531861A5 (cg-RX-API-DMAC7.html)
JP2022500066A5 (cg-RX-API-DMAC7.html)
JP2022530656A5 (cg-RX-API-DMAC7.html)
JP2020537544A5 (cg-RX-API-DMAC7.html)
JP2018108113A5 (cg-RX-API-DMAC7.html)
JP2022553406A5 (cg-RX-API-DMAC7.html)
JP2020522269A5 (cg-RX-API-DMAC7.html)
JP6824169B2 (ja) 改変g6pcをコードするアデノ随伴ウイルスベクターおよびその使用
US12344857B2 (en) Viral vector production
JP2023545433A5 (cg-RX-API-DMAC7.html)
JP2022511453A5 (cg-RX-API-DMAC7.html)
JP7531933B2 (ja) 新規なイントロン断片
JP2025539750A (ja) 前頭側頭型認知症の遺伝子治療
JP2024542950A5 (cg-RX-API-DMAC7.html)
JP2024517104A5 (cg-RX-API-DMAC7.html)
JP2023553005A5 (cg-RX-API-DMAC7.html)
JP2025513066A5 (cg-RX-API-DMAC7.html)
JP2024543211A5 (cg-RX-API-DMAC7.html)